About healthdec_rljyp3

This author has not yet filled in any details.
So far healthdec_rljyp3 has created 34 blog entries.

NAMS 2018: We Can’t Ignore Health Conditions Affecting Half the World’s Population for Half of Their Adult Lives

The North American Menopause Society (NAMS) will hold its 2018 Annual Meeting October 3-6 in San Diego, California. The medical community recognizes the NAMS Annual Meeting as a significant event, and yet it is easy to underestimate the meeting’s full importance. Think about it. Menopause profoundly affects the health and quality of life of about [...]

NAMS 2018: We Can’t Ignore Health Conditions Affecting Half the World’s Population for Half of Their Adult Lives 2018-10-02T17:47:50+00:00

Women’s Health Oncology Success Story: Rapid Enrollment and Reduced Cost

Health Decisions completed a metastatic breast cancer study a full year ahead of schedule and saved the sponsor approximately $2 million in direct costs through agile enrollment and a tiered global enrollment strategy, demonstrating the ability to achieve rapid enrollment and reduced cost in oncology clinical trials.

Women’s Health Oncology Success Story: Rapid Enrollment and Reduced Cost 2017-09-05T21:45:49+00:00

Projecting Outcomes and Combining Phases in an Oncology Biologics Program

For an oncology biologic program, we worked with the client to combine PoC and dosing studies into a single study based on ability to continuously track outcomes. One of the other key features was continuously projecting where the study would end up, based on data to date. The design provided for stopping the study [...]

Projecting Outcomes and Combining Phases in an Oncology Biologics Program 2017-09-05T21:34:05+00:00

Saluting Trial Participants on International Clinical Trials Day

In observing International Clinical Trials Day for 2017 on May 19, Health Decisions wishes to thank all those who participate in clinical trials. Health Decisions especially thanks patients enrolled in our current trials but we want to thank trial participants everywhere for making clinical development possible. While sponsors and CROs like Health Decisions make every [...]

Saluting Trial Participants on International Clinical Trials Day 2018-08-14T21:05:25+00:00

Women’s Health Week 2017: Spotlight on Infectious Conditions

For National Women's Health Week last year, this blog focused on the need for progress in a variety of areas in which women have unmet medical needs. Last year's post mentioned the need for progress in noninvasive diagnostics and therapeutics for osteoporosis, female sexual dysfunction, endometriosis, bacterial vaginosis and uterine fibroids. This year we want [...]

Women’s Health Week 2017: Spotlight on Infectious Conditions 2018-08-14T21:06:25+00:00

Differences Between Drug and Medical Device Trials: CSRs

While drugs and medical devices are both essential in modern medical care, there are times when standard clinical development processes seem to treat medical devices as an afterthought. For example, medical writers for a CRO conducting studies of both drugs and devices must learn to interpret a drug-centric guidance document to author an appropriate Clinical [...]

Differences Between Drug and Medical Device Trials: CSRs 2018-08-14T21:07:18+00:00

Thinking of Women’s Healthcare Needs on International Women’s Day

As a CRO focused on clinical development of products to improve women's healthcare, Health Decisions sees International Women's Day as an occasion to redouble our commitment to enabling drug, diagnostics and medical device companies to bring new women's health products to market as rapidly and efficiently as possible. For Health Decisions, the scope of women's [...]

Thinking of Women’s Healthcare Needs on International Women’s Day 2018-08-14T21:08:12+00:00

Addressing High Failure Rates in Drug Development

FDA has published an excellent report on 22 instances in which phase 2 and phase 3 trials had divergent results. Appendix A of the report provides justifications for essential elements of modern clinical trials, including a control group, randomization and blinding. In addition, Appendix A highlights risks of techniques for improving efficiency in early development, [...]

Addressing High Failure Rates in Drug Development 2018-08-14T21:09:03+00:00

2017 – Time for a Bold R&D Initiative in Women’s Health

Despite NIH and FDA women's health policy initiatives previously described in this blog, the list of novel drugs approved by FDA in 2016 includes only one product for a woman-specific health indication. FDA granted accelerated approval in December 2016 for rucaparib (Rubraca™), a Clovis Oncology PARP inhibitor for ovarian cancer. Rubraca is indicated for patients [...]

2017 – Time for a Bold R&D Initiative in Women’s Health 2018-08-14T21:09:50+00:00

Settling on a Framework for LDT Regulation: Update

Update: The FDA post-election statement on delaying implementation of the agency's draft guidance on LDTs affirms the status quo - for now. The delay allays the concerns of some stakeholders about potential effects of greater FDA involvement in LDT regulation, such as slowing innovation in diagnostics and patient access to the most advanced diagnostics and, [...]

Settling on a Framework for LDT Regulation: Update 2018-08-14T21:10:39+00:00
SUBMIT RFP